It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Objective: The objective was to establish a machine learning-based model for predicting the occurrence and mortality of nonpulmonary sepsis-associated ARDS. Methods: 80% of sepsis patients selected randomly from the MIMIC-IV database, without prior pulmonary conditions and with nonpulmonary infection sites, were used to construct prediction models through machine learning techniques (including K-nearest neighbour, extreme gradient boosting, support vector machine, deep neural network, and decision tree methods). The remaining 20% of patients were utilized to validate the model’s accuracy. Additionally, local data were employed for further model validation. Results: A total of 11,409 patients were included, with the most common type of infection being bloodstream infection. A total of 7,632 (66.9%) patients developed nonpulmonary sepsis-associated ARDS (NPS-ARDS). Patients with NPS-ARDS had significantly longer ICU stays (6.2 ± 5.2 days vs. 4.4 ± 3.7 days, p < 0.01) and higher 28-day mortality rates (19.5% vs. 14.9%, p < 0.01). Both internal and external validation demonstrated that the model constructed with the extreme gradient boosting method had high accuracy. In the internal validation, the model predicted NPS-ARDS and mortality in such patients with accuracies of 77.5% and 71.8%, respectively. In the external validation, the model predicted NPS-ARDS and mortality in these patients with accuracies of 78.0% and 81.4%, respectively. Conclusion: The model established via the extreme gradient boosting method can predict the occurrence and mortality of nonpulmonary sepsis-associated ARDS to a certain extent.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Jinling Clinical Medical College of Nanjing Medical University, Department of Emergency Medicine, Nanjing, China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984); Nantong Third People’s Hospital, Affiliated Nantong Hospital 3 of Nantong University, Critical Care Medicine, Nantong, China (GRID:grid.260483.b) (ISNI:0000 0000 9530 8833)
2 Trip.com Group Ltd, Ctrip Infrastructure Service, Shanghai, China (GRID:grid.497043.d)
3 Jinling Clinical Medical College of Nanjing Medical University, Department of Emergency Medicine, Nanjing, China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984)
4 Nantong Third People’s Hospital, Affiliated Nantong Hospital 3 of Nantong University, Critical Care Medicine, Nantong, China (GRID:grid.260483.b) (ISNI:0000 0000 9530 8833)